Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
about
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsOptimizing treatment success in multiple sclerosisTreating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisThe Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Dimethyl Fumarate: A Review in Relapsing-Remitting MS.Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.Does Nrf2 help nerves to survive?The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
P2860
Q26752859-35F50F94-53D9-4366-A0A4-E520C4520511Q26771968-9BA38B4D-54AC-4041-A944-92E4C96399FFQ30965003-B02FE609-7FB0-4341-AA39-C8D4C86E2DF1Q36202826-46355AFC-0BCB-4595-A7D7-FCF08F41D269Q36484448-E016FDE4-49AC-4A5A-9F5D-333600F3BA93Q37459099-4EF1E61B-C59F-4A2F-AB39-ADED4FE62E3CQ38371842-845C4861-D0C8-4D97-8F3C-218297A02707Q38534132-6DE21197-0BCA-4614-B590-C62183D26A97Q38675014-BA94447B-862D-4257-B794-516C97293598Q39298719-47F6AEA1-EBB0-4267-9026-E26AB9E8F3F0Q40816642-22ED5C2F-3A37-4E1C-8893-9821828C1AD4Q48168382-5B89AFBA-0491-415C-ACCF-140254B06268Q49800939-14702622-415C-4043-A50A-B9EF9FD30428Q52806769-542C3326-241F-4C1E-8E09-4F9B1D14684CQ58756156-26A18EF4-9454-4247-9769-6A66D463538D
P2860
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@ast
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@en
type
label
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@ast
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@en
prefLabel
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@ast
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@en
P2093
P2860
P1433
P1476
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
@en
P2093
CONFIRM study investigators
Claudia A M Wheeler-Kingshott
Daniel J Tozer
David G MacManus
David H Miller
J Theodore Phillips
Katherine T Dawson
Mariko Kita
Mary Goodsell
Minhua Yang
P2860
P304
P356
10.1212/WNL.0000000000001360
P407
P577
2015-02-13T00:00:00Z